[go: up one dir, main page]

AR018286A1 - Composicion farmaceutica que en calidad de principio activo contiene la asociacion de metformina y fibrato, y la utilizacion de esta asociacion para preparar medicamentos - Google Patents

Composicion farmaceutica que en calidad de principio activo contiene la asociacion de metformina y fibrato, y la utilizacion de esta asociacion para preparar medicamentos

Info

Publication number
AR018286A1
AR018286A1 ARP990100598A ARP990100598A AR018286A1 AR 018286 A1 AR018286 A1 AR 018286A1 AR P990100598 A ARP990100598 A AR P990100598A AR P990100598 A ARP990100598 A AR P990100598A AR 018286 A1 AR018286 A1 AR 018286A1
Authority
AR
Argentina
Prior art keywords
metformin
fibrate
asfciation
association
quality
Prior art date
Application number
ARP990100598A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR018286A1 publication Critical patent/AR018286A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El campo de aplicacion del invento lo constituye el tratamiento de la hiperglicemia de la diabetes no insulinadependiente. Se ha tratado de encontrar unagente de tratamiento, mejor que los conocidos y que sirviera, además, para tratar a pacientes quesufren de diabetes no insulinadependientes y tambiénhiperlipemia. Se propone una composicion que comprende en calidad de principios activos, la metformina y un fibrato elegido entre el fenofibrato y labezafibrato. Se produce un efecto sinérgico entre la metformina y dichos fibratos que conducen a una mejora neta de la hiperglicemia, tanto en pacientesdiabéticos que presentan hiperlipemia como en los que no la presentan.
ARP990100598A 1998-02-12 1999-02-12 Composicion farmaceutica que en calidad de principio activo contiene la asociacion de metformina y fibrato, y la utilizacion de esta asociacion para preparar medicamentos AR018286A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie

Publications (1)

Publication Number Publication Date
AR018286A1 true AR018286A1 (es) 2001-11-14

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100598A AR018286A1 (es) 1998-02-12 1999-02-12 Composicion farmaceutica que en calidad de principio activo contiene la asociacion de metformina y fibrato, y la utilizacion de esta asociacion para preparar medicamentos

Country Status (27)

Country Link
US (1) US6372790B1 (es)
EP (1) EP1054665B1 (es)
JP (1) JP4767411B2 (es)
KR (1) KR100567608B1 (es)
CN (1) CN1151785C (es)
AR (1) AR018286A1 (es)
AT (1) ATE204754T1 (es)
AU (1) AU746821B2 (es)
BR (1) BRPI9907866B8 (es)
CA (1) CA2320039C (es)
CZ (1) CZ290101B6 (es)
DE (1) DE69900249T2 (es)
DK (1) DK1054665T3 (es)
ES (1) ES2162517T3 (es)
FR (1) FR2774591B1 (es)
HU (1) HU224619B1 (es)
ID (1) ID26254A (es)
MY (1) MY118164A (es)
NO (1) NO328314B1 (es)
PL (1) PL196874B1 (es)
PT (1) PT1054665E (es)
RU (1) RU2207850C2 (es)
SK (1) SK283212B6 (es)
TW (1) TW518222B (es)
UA (1) UA70315C2 (es)
WO (1) WO1999040904A2 (es)
ZA (1) ZA991077B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AU2001236457A1 (en) * 2000-01-13 2001-07-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
CA2509101A1 (en) 2002-12-13 2004-07-01 Jagotec Ag A topical nanoparticulate spironolactone formulation
WO2004069259A1 (ja) * 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
RU2241449C1 (ru) * 2003-09-25 2004-12-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция для лечения диабета (варианты)
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
KR101329369B1 (ko) * 2003-12-19 2013-11-14 오메가 바이오 파마(아이.피.3) 리미티드 당뇨 치료용 조성물 및 방법
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
WO2005074909A1 (ja) * 2004-02-09 2005-08-18 Aska Pharmaceutical Co., Ltd. 併用医薬
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
CA2657394A1 (en) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
BR112015000368A2 (pt) * 2012-07-10 2017-06-27 Thetis Pharmaceuticals Llc forma de tri-sais de metformina
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
MX2016016830A (es) 2014-06-18 2017-07-07 Thetis Pharmaceuticals Llc Complejos de aminoacidos minerales de agentes activos.
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (en) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Stable pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
FR2264525B1 (es) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
DE3729209A1 (de) 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
KR100567608B1 (ko) 2006-04-04
AU2923399A (en) 1999-08-30
MY118164A (en) 2004-09-30
SK283212B6 (sk) 2003-03-04
CA2320039C (en) 2008-07-22
FR2774591B1 (fr) 2000-05-05
SK11562000A3 (sk) 2000-12-11
FR2774591A1 (fr) 1999-08-13
EP1054665A2 (en) 2000-11-29
WO1999040904A3 (en) 1999-09-30
NO20004056L (no) 2000-08-11
NO328314B1 (no) 2010-01-25
PT1054665E (pt) 2002-02-28
RU2207850C2 (ru) 2003-07-10
CN1151785C (zh) 2004-06-02
ID26254A (id) 2000-12-07
EP1054665B1 (en) 2001-08-29
KR20010040925A (ko) 2001-05-15
AU746821B2 (en) 2002-05-02
DE69900249T2 (de) 2002-06-13
JP2002502869A (ja) 2002-01-29
TW518222B (en) 2003-01-21
US6372790B1 (en) 2002-04-16
ES2162517T3 (es) 2001-12-16
ZA991077B (en) 1999-08-11
CZ290101B6 (cs) 2002-05-15
BR9907866A (pt) 2000-10-31
WO1999040904A2 (en) 1999-08-19
BRPI9907866B8 (pt) 2021-05-25
CN1290160A (zh) 2001-04-04
CA2320039A1 (en) 1999-08-19
PL342665A1 (en) 2001-07-02
JP4767411B2 (ja) 2011-09-07
DK1054665T3 (da) 2001-12-27
DE69900249D1 (de) 2001-10-04
UA70315C2 (en) 2004-10-15
NO20004056D0 (no) 2000-08-11
HUP0100801A2 (hu) 2001-08-28
CZ20002828A3 (cs) 2000-11-15
ATE204754T1 (de) 2001-09-15
HK1034913A1 (en) 2001-11-09
PL196874B1 (pl) 2008-02-29
HU224619B1 (hu) 2005-11-28
BRPI9907866B1 (pt) 2017-08-15
HUP0100801A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
AR018286A1 (es) Composicion farmaceutica que en calidad de principio activo contiene la asociacion de metformina y fibrato, y la utilizacion de esta asociacion para preparar medicamentos
ES2150889T1 (es) Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii.
ES2191068T3 (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
AR023715A1 (es) Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
UY26425A1 (es) Formulación y método antidiabético
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
UY26296A1 (es) Tratamiento medicamentoso del síndrome de piernas inquietas
ES2148838T3 (es) Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer.
CR7140A (es) Antranilamidas con una cadena colateral de un heteroarylsulfonil, metodos para la produccion de los mismos, su uso como medicamento o agente diagnostico y preparaciones farmaceuticas contenidas en dichos compuestos
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
BR9814299A (pt) Aminobiguanidas e o seu uso para desinfetarlentes de contato e preservar composiçõesfarmacêuticas
ES2142388T3 (es) Agente anti-diabetico.
MX9304564A (es) Combinaciones de relajante muscular-ibuprofen.
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
AR030957A1 (es) Composiciones de analgesico y glucosamina
ES2143467T3 (es) Agente terapeutico para el tratamiento de las heridas.
PT1001775E (pt) Medicamento contendo ioimbina e arginina para tratamento de disfuncao erectil
MX9701477A (es) Composicion para aliviar el dolor, que contiene un analgesico no narcotico y un mejorador de analgesia.
ES2192779T3 (es) Modificacion cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico.
ES2177671T3 (es) Benzamida enterocinetica.
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
AR019346A1 (es) Composicion de tenido para fibras queratinicas con un colorante directo cationico y un polimero espesante
AR049421A1 (es) Mezclas insecticidas sinergicas
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications

Legal Events

Date Code Title Description
FG Grant, registration